27 Results for "

anti CD20

" in MedChemExpress (MCE) Product Catalog:
Products (27)

27 Results for "anti CD20" in MCE Product Catalog:

16
16 Publications Verification
Cat. No.: HY-P9913
CAS No.: 174722-31-7
Synonyms: anti-Human CD20 type I, Chimeric antibody; HSDB 7455; IDEC-C2B8
Rituximab is an anti-CD20 chimeric monoclonal antibody used for research of certain autoimmune diseases and cancer.
loading...
    loading...
16
16 Publications Verification
Cat. No.: HY-P9913A
CAS No.: 174722-31-7
Rituximab (anti-CD20) is an anti-CD20 chimeric monoclonal antibody used to treat certain autoimmune diseases and types of cancer .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-P99731
CAS No.: 899796-83-9
Synonyms: hLL1; MEDI-115

Target:  

CD74

Research Areas:  

Cancer

Milatuzumab (hLL1; MEDI-115) is a humanized anti-CD74 monoclonal antibody. CD74, a integral membrane protein, is associated with the promotion of B-cell growth and survival. Milatuzumab causes free radical oxygen generation, and loss of mitochondrial membrane potential. Milatuzumaba also decreases CD20/CD74 aggregates and cell adhesion, to lead to cell death .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P9910
CAS No.: 949142-50-1
Synonyms: GA101; anti-Human CD20 type II, Humanized antibody
Target:  

CD20

Research Areas:  

Cancer

Obinutuzumab (GA101) a Type II CD20 humanized IgG1 monoclonal antibody in development for non-Hodgkin lymphoma.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P990806

Target:  

CD20

Research Areas:  

Metabolic Disease Cancer

Anti-Mouse CD20 Antibody (MB20-11) is a kind of mouse IgG2c antibody inhibitor, targeting to CD20. Anti-Mouse CD20 Antibody (MB20-11) can deplete mature B cells in lymphoid tissues. Anti-Mouse CD20 Antibody (MB20-11) can be used for the researches of cancer, immunology and metabolic Disease, such as lymphoma and diabetes .
loading...
    loading...
Cat. No.: HY-P9961
CAS No.: 679818-59-8
Synonyms: GSK1841157; OMB-157

Target:  

CD20

Research Areas:  

Cancer

Ofatumumab is a fully human anti-CD20 monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in CD20-expressing B lymphocytes. Ofatumumab has strong lytic activity against CD20-positive B lymphocytes and eliminates CD20-positive tumor cells through ADCC and CDC. Ofatumumab is particularly effective against drug-resistant cells with low CD20 expression and can be applied to the research of chronic lymphocytic leukemia (CLL) .
loading...
    loading...
Cat. No.: HY-P99038
CAS No.: 1801338-64-6
Synonyms: REGN1979

Target:  

CD20 CD3

Research Areas:  

Cancer

Odronextamab is a stable humanized IgG4 CD20 × CD3 bispecific antibody that binds to CD3 on T cells and CD20 on B cells, triggering anti-tumor activity. Odronextamab is expected to be used in oncology research .
loading...
    loading...
Cat. No.: HY-P99326
CAS No.: 192391-48-3
Synonyms: anti-Human CD20 Recombinant antibody; V10XA53

Target:  

CD20

Research Areas:  

Cancer

Tositumomab (Anti-Human CD20 Recombinant Antibody) is a mouse-derived IgG2a monoclonal antibody, targeting to human CD20. Tositumomab can deplete B cells. Tositumomab can be used for the research of cancer, such as lymphoma .
loading...
    loading...
Cat. No.: HY-P9960
CAS No.: 637334-45-3
Synonyms: 2H7; PRO70769; RG1594

Target:  

CD20

Research Areas:  

Inflammation/Immunology

Ocrelizumab (Ocrevus) is a humanized anti-CD20 monoclonal antibody. Ocrelizumab can induce B cell depletion and inhibit multiple sclerosis lesions in mice through antibody dependent cytotoxicity (ADCC) .
loading...
    loading...
Cat. No.: HY-P990139

Target:  

CD20

Research Areas:  

Inflammation/Immunology

Anti-Mouse CD20 Antibody (AISB12) is an anti-mouse CD20 IgG2a monoclonal antibody. Anti-Mouse CD20 Antibody (AISB12) can deplete B cells. Anti-Mouse CD20 Antibody (AISB12) can be used for research on immunology .
loading...
    loading...
Cat. No.: HY-P99224
CAS No.: 728917-18-8
Synonyms: IMMU-106; hA20

Target:  

Integrin

Research Areas:  

Cancer

Veltuzumab (IMMU-106) is a humanized anti-CD20 monoclonal antibody. Veltuzumab has low EC50 value of 0.08-0.09 μg/mL in the Daudi cell line. Veltuzumab can be used for the research of cancer including non-Hodgkin lymphoma (NHL) .
loading...
    loading...
Cat. No.: HY-P99308
CAS No.: 1169956-08-4
Synonyms: AME 133v; LY 2469298; Humanized anti-MS4A1 Recombinant antibody

Target:  

CD20

Research Areas:  

Cancer

Ocaratuzumab (AME 133v) is an Fc-engineered humanized IgG1 anti-CD20 monoclonal antibody, with a Kd of ~100 pM. Ocaratuzumab exhibits more effective antibody-dependent cell-mediated cytotoxicity (ADCC) .
loading...
    loading...
Cat. No.: HY-P990138

Target:  

CD20

Anti-Monkey/Human CD20 Antibody (2H7) is a mouse-derived IgG2b κ type antibody inhibitor, targeting to monkey/human CD20. Anti-Monkey/Human CD20 Antibody (2H7) specifically depletes B cells. Anti-Monkey/Human CD20 Antibody (2H7) can be used for the researches of inflammation and metabolic disease, such as diabetes and experimental autoimmune encephalomyelitis .
loading...
    loading...
Cat. No.: HY-P99759
CAS No.: 1622189-43-8
Synonyms: IL-15N72D

Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology Cancer

Nogapendekin alfa his tag is an immunostimulant that binds to the IL-2RβγC complex on immune cells. Nogapendekin alfa his tag stimulates the proliferation and activation of natural killer cells and CD8 + T cells, upregulates the expression of granzyme B and perforin, and activates the innate and adaptive immune branches. Nogapendekin alfa his tag forms ALT-803 with IL-15RαSuFc; this complex has an extended biological half-life, improved biodistribution and retention in lymphoid tissues, enhances natural killer cell-mediated rituximab-dependent cellular cytotoxicity, and reduces tumor burden and improves survival when combined with anti-CD20 monoclonal antibody therapy. Nogapendekin alfa his tag can be used in the research of non-Hodgkin's lymphoma .
loading...
    loading...
Cat. No.: HY-P99952
CAS No.: 2249927-04-4
Synonyms: SCT400
Ripertamab (SCT400) is a recombinant human-mouse chimeric anti-CD20 IgG1κ monoclonal antibody. As an immunomodulator, ripertamab reduces the levels of pathogenic autoantibodies, alleviates immune complex deposition, and blocks the antigen-presenting function of cells. Ripertamab depletes CD20-positive cells. Ripertamab can induce infusion-related reactions, pulmonary toxicity, neutropenia and thrombocytopenia. Ripertamab is applicable to research related to non-Hodgkin's lymphoma, primary membranous nephropathy and idiopathic membranous nephropathy .
loading...
    loading...
Cat. No.: HY-P991225

Target:  

Fc Receptor (FcR) CD20

Research Areas:  

Inflammation/Immunology Cancer

BI-1206 is a recombinant and antagonistic human monoclonal antibody targeting FcγRIIB (CD32B). BI-1206 can block CD20 internalization induced by Rituximab (HY-P9913) itself or combined with others including Ibrutinib (HY-10997), Venetoclax (HY-15531), and CHOP. BI-1206 can enhance or recover the activity of Rituximab or other anti-CD20 monoclonal antibodies. BI-1206 has cytolytic activity against malignant B cells. BI-1206 can be studied for cancer research such as mantle cell lymphoma (MCL) .
loading...
    loading...
Cat. No.: HY-P991547
CAS No.: 922534-56-3

Target:  

CD20 Apoptosis

Research Areas:  

Inflammation/Immunology Cancer

Anti-CD20 Antibody (mAb 1.5.3) is a fully human IgG1 anti-CD20 antibody. Anti-CD20 Antibody (mAb 1.5.3) evokes enhanced pro-apoptotic activity in vitro. Anti-CD20 Antibody (mAb 1.5.3) mediated both complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. Anti-CD20 Antibody (mAb 1.5.3) demonstrates enhanced anti-tumor activity in various tumor xenograft models. Anti-CD20 Antibody (mAb 1.5.3) produces a superior B-cell depletion profile in lymph node organs and bone marrow in a primate pharmacodynamic model. Anti-CD20 Antibody (mAb 1.5.3) can be studied in research for B-cell maglignancies .
loading...
    loading...
Cat. No.: HY-P990350

Target:  

Inhibitory Antibodies

Research Areas:  

Inflammation/Immunology

Anti-CD20 Antibody is a humanized antibody expressed in CHO that targets CD20/MS4A1. The Anti-CD20 Antibody is composed of huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CD20 Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
loading...
    loading...
Cat. No.: HY-P992060
Target:  

CD20 NF-κB

Research Areas:  

Inflammation/Immunology Cancer

Anti-Mouse CD20 Antibody (18B12) is a B cell depleting agent that targets mouse CD20. Anti-Mouse CD20 Antibody (18B12) not only inhibits the growth of mesothelioma, lung cancer and thymoma, but also significantly enhances the efficacy of adenoviral tumor antigen vaccines and induces tumor regression by increasing the number of tumor-specific CD8 + T cells. Anti-Mouse CD20 Antibody (18B12) reduces B cell infiltration into the central nervous system of mice with experimental autoimmune encephalomyelitis, and delays motor dysfunction and neuronal death after spinal cord injury by alleviating inflammatory responses and tissue damage. Anti-Mouse CD20 Antibody (18B12) is widely applicable to research in fields related to mesothelioma, lung cancer, thymoma, experimental autoimmune encephalomyelitis and spinal cord injury .
loading...
    loading...
Cat. No.: HY-P991514

Target:  

CD20

Research Areas:  

Cancer

MIL62 is an anti-CD20 monoclonal antibody. MIL62 shows enhanced affinity for the FcγRⅢa receptors and direct B-cell killing effects. MIL62 has antibody-dependent cell-mediated cytotoxicity (ADCC) activity. MIL62 can be used for the study of non-Hodgkin lymphoma (NHL) .
loading...
    loading...